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protein hemagglutinin (HA) (Eggink et al., 2014) but these observations
have not yet been translated into humans.
Amongst additional functions triggered by Abs, Ab-dependent cellu-
lar cytotoxicity (ADCC)mediates antiviral activities through the binding
of cell surface Ags by IgG subtypes on target cells. This ultimately leads
to the lysis of the target cells by secreted lytic enzymes from effectorInﬂuenza
ADCC
NK cells
VaccineThe last century haswitnessed incredible progresses in the control of
infectious diseases. However, respiratory pathogens continue to threat-
en humans and cause serious public health and economic problems. Not
only emerging pathogens but also viruses that have been known for a
while continue to cause widespread issues (Summary analysis of 2014
survey of National Inﬂuenza Centres in the WHO Global Inﬂuenza
Surveillance and Response System, 2014). Despite the relative efﬁcacy
of the inactivated vaccine against inﬂuenza A viruses (IAV) has been
shown for many years, this virus is still responsible for seasonal wide-
spread morbidity and mortality. These outbreaks are usually associated
with mild symptoms but can also result in 3 to 5 million cases of severe
illnesses, especially amongst elderly and young children. Inﬂuenza virus
still accounts for 250,000 to 500,000 deaths each year during epidemic
episodes (Summary analysis of 2014 survey of National Inﬂuenza
Centres in the WHO Global Inﬂuenza Surveillance and Response
System, 2014). This is due to the continuous antigenic drift that leads
to vaccine mismatch and therefore negatively impacts on its effective-
ness (Krammer and Palese, 2015). Moreover, more sporadically, pan-
demics due to highly virulent strains or transversal infections of
animal strains to humans represent another important threat (Palese,
2004). In this context, it is of the utmost importance to urgently develop
universal inﬂuenza vaccines. Current vaccines are yearly updated on the
basis of the circulating strains but unfortunately mainly generate neu-
tralizing antibodies (Abs) directed against epitopes contained in highly
variable regions (Gerdil, 2003). Nevertheless pre-clinical studies have
demonstrated promising data through the generation of neutralizingom.2016.04.029.
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cells. This secretion follows the recognition of Fc region of surface
bound Abs by FcγRIIIα (CD16)-expressing cytotoxic effector cells from
both innate and adaptive immunity such as Natural Killer (NK) cells or
CD8+ T cells. ADCC directed against IAV has been recognized for a
long time(Jegaskanda et al., 2014). Since this class of Abs can target
muchmore conserved proteins, understanding ADCC mechanisms dur-
ing IAV infection might help in the development of universal inﬂuenza
vaccines. For instance, a vaccine trial in HIV patients has been demon-
strated protective in part through ADCC-mediating Abs(Madhavi et al.,
2012).
In this issue, Vanderven and colleagues evidence in human samples
fromhealthy inﬂuenza-exposed adults or symptomatic donors the exis-
tence of IAV-speciﬁc Abs capable of ADCC activity through NK cells
(Vanderven et al., 2016). Interestingly these opsonizingAbs are directed
against the highly conserved internal viral proteins nucleoprotein (NP)
and matrix 1(M1) (~90% of identity in amino acid sequences between
strains) from two different strains of IAV (H1N1/2009pdm and H3N2/
2005). An increase for such cross-protective Abs was found in sera of
naturally IAV-exposed humans suggesting that this class of Abs can po-
tentially mediate heterologous response to various IAV strains during
active infection. However, authors failed to detect rise in NK cell-medi-
ated ADCC activity in volunteers experimentally exposed to IAV (H3N2/
2005). The reasons for such a discrepancy are currently unknown. It is
possible that the route/dose of infection as well as the strain used mat-
ters in the development of NK cell activating Abs. Other clinical studies
investigating the contribution of these parameters will be informative
to answer this question.
The presence and functionality of NP- andM1-speciﬁc NK cell-medi-
ated ADCC in animalmodels includingnon-human primates has already
been demonstrated (Jegaskanda et al., 2014). From a mechanistic point
of view, the relevance of ADCC mediated against internal proteins re-
mains puzzling. Given that NP and M1 are only minimally exposed at
the cell surface during IAV life cycle, it will be important to determine
the precise molecular/cellular mechanisms underlying NK cell-mediat-
ed ADCC. Although these Abs could mediate direct protection through
opsonization of infected/dying cells, another explanation might involveC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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mation) that could lead to enhanced immune responses.
The origin of this class of Abs is currently unknown. Do they arise
from speciﬁc B cell subsets? As suggested in this study, it is tempting
to answer in the afﬁrmative. Actually while most of the donors (healthy
inﬂuenza-exposed and symptomatic) presented detectable levels of
persistent NP- and M1-speciﬁc ADCC-mediating Abs, authors failed to
concomitantly detect classical neutralizing Abs. Therefore, it will be im-
portant to understand the mechanisms and B cell populations involved
in the generation of cross-reactive Abs.
For a long time, immunologists have focused their attention on the
sole role of neutralizing Abs for vaccination efﬁcacy. It is now clear
that other Ab-dependentmechanisms can play relevant biological func-
tions. The existence and persistence of Abs capable of NK cell-mediated
ADCC against conserved viral proteins in patients with IAV infection is
an important step in our comprehension of the immune responses
against these viruses. This observation and their recognized relevance
in experimental models of IAV infection should encourage a better in-
vestigation of ADCC-mediating Abs as a putative predictive parameter
in vaccine efﬁcacy and could further support the development of a “Uni-
versal inﬂuenza vaccine”.References
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